{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T18:50:55Z","timestamp":1775069455709,"version":"3.50.1"},"reference-count":48,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2021,12,1]],"date-time":"2021-12-01T00:00:00Z","timestamp":1638316800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,12,1]],"date-time":"2021-12-01T00:00:00Z","timestamp":1638316800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,10,8]],"date-time":"2021-10-08T00:00:00Z","timestamp":1633651200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","gynecologiconcology-online.net","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Gynecologic Oncology"],"published-print":{"date-parts":[[2021,12]]},"DOI":"10.1016\/j.ygyno.2021.09.025","type":"journal-article","created":{"date-parts":[[2021,10,11]],"date-time":"2021-10-11T12:51:04Z","timestamp":1633956664000},"page":"465-472","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":8,"title":["Results of TRIO-14, a phase II, multicenter, randomized, placebo-controlled trial of carboplatin-paclitaxel versus carboplatin-paclitaxel-ganitumab in newly diagnosed epithelial ovarian cancer"],"prefix":"10.1016","volume":"163","author":[{"given":"G.E.","family":"Konecny","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A.E. Wahner","family":"Hendrickson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"T.M.","family":"Davidson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"B.J.","family":"Winterhoff","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"S.","family":"Ma","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"S.","family":"Mahner","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J.","family":"Sehouli","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"P.A.","family":"Fasching","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"G.","family":"Feisel-Schwickardi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M.","family":"Poelcher","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"L.D.","family":"Roman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A.","family":"Rody","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"B.Y.","family":"Karlan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"S.A.","family":"Mullany","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"H.","family":"Chen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"I.L.","family":"Ray-Coquard","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"D.M.","family":"Provencher","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A.","family":"Yachnin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"P.H.","family":"Cottu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J.A.","family":"Glaspy","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"P.","family":"Haluska","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"D.J.","family":"Slamon","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.ygyno.2021.09.025_bb0005","first-page":"7","article-title":"Cancer statistics, 2020","volume":"70","author":"Siegel","year":"2020","journal-title":"CA Cancer J. Clin."},{"issue":"2","key":"10.1016\/j.ygyno.2021.09.025_bb0010","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1016\/j.critrevonc.2013.08.017","article-title":"Sensitivity and resistance to treatment in the primary management of epithelial ovarian cancer","volume":"89","author":"Colombo","year":"2014","journal-title":"Crit. Rev. Oncol. Hematol."},{"issue":"25","key":"10.1016\/j.ygyno.2021.09.025_bb0015","doi-asserted-by":"crossref","first-page":"2416","DOI":"10.1056\/NEJMoa1911361","article-title":"Olaparib plus bevacizumab as first-line maintenance in ovarian cancer","volume":"381","author":"Ray-Coquard","year":"2019","journal-title":"N. Engl. J. Med."},{"issue":"8","key":"10.1016\/j.ygyno.2021.09.025_bb0020","doi-asserted-by":"crossref","first-page":"803","DOI":"10.1016\/S0046-8177(03)00291-0","article-title":"Expression and distribution of insulin-like growth factor-1 receptor in human carcinomas","volume":"34","author":"Ouban","year":"2003","journal-title":"Hum. Pathol."},{"issue":"1","key":"10.1016\/j.ygyno.2021.09.025_bb0025","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1016\/j.ghir.2014.10.002","article-title":"The dichotomy of the insulin-like growth factor 1 receptor: RTK and GPCR: friend or foe for cancer treatment?","volume":"25","author":"Crudden","year":"2015","journal-title":"Growth Hormon. IGF Res."},{"issue":"3","key":"10.1016\/j.ygyno.2021.09.025_bb0030","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1042\/BJ20061709","article-title":"Characterization of insulin\/IGF hybrid receptors: contributions of the insulin receptor L2 and Fn1 domains and the alternatively spliced exon 11 sequence to ligand binding and receptor activation","volume":"403","author":"Benyoucef","year":"2007","journal-title":"Biochem. J."},{"issue":"7","key":"10.1016\/j.ygyno.2021.09.025_bb0035","doi-asserted-by":"crossref","first-page":"873","DOI":"10.1016\/j.bcp.2008.07.027","article-title":"Characterization of IRA\/IRB hybrid insulin receptors using bioluminescence resonance energy transfer","volume":"76","author":"Blanquart","year":"2008","journal-title":"Biochem. Pharmacol."},{"issue":"8","key":"10.1016\/j.ygyno.2021.09.025_bb0040","doi-asserted-by":"crossref","first-page":"1214","DOI":"10.1158\/1535-7163.MCT-05-0048","article-title":"Inhibition of insulin-like growth factor-I receptor (IGF-IR) signaling and tumor cell growth by a fully human neutralizing anti-IGF-IR antibody","volume":"4","author":"Wang","year":"2005","journal-title":"Mol. Cancer Ther."},{"issue":"19","key":"10.1016\/j.ygyno.2021.09.025_bb0045","doi-asserted-by":"crossref","first-page":"4270","DOI":"10.1158\/1078-0432.CCR-14-2518","article-title":"Molecular pathways: clinical applications and future direction of insulin-like growth Factor-1 receptor pathway blockade","volume":"21","author":"Iams","year":"2015","journal-title":"Clin. Cancer Res."},{"issue":"2","key":"10.1016\/j.ygyno.2021.09.025_bb0050","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1006\/excr.1997.3861","article-title":"Biological characterization of human epithelial ovarian carcinoma cells in primary culture: the insulin-like growth factor system","volume":"238","author":"Conover","year":"1998","journal-title":"Exp. Cell Res."},{"issue":"2","key":"10.1016\/j.ygyno.2021.09.025_bb0055","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1016\/j.ygyno.2004.10.012","article-title":"High insulin-like growth factor-2 (IGF-2) gene expression is an independent predictor of poor survival for patients with advanced stage serous epithelial ovarian cancer","volume":"96","author":"Sayer","year":"2005","journal-title":"Gynecol. Oncol."},{"issue":"11","key":"10.1016\/j.ygyno.2021.09.025_bb0060","doi-asserted-by":"crossref","first-page":"2947","DOI":"10.1158\/1078-0432.CCR-13-3448","article-title":"Ganitumab (AMG 479) inhibits IGF-II-dependent ovarian cancer growth and potentiates platinum-based chemotherapy","volume":"20","author":"Beltran","year":"2014","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.ygyno.2021.09.025_bb0065","doi-asserted-by":"crossref","DOI":"10.1200\/jco.2013.31.15_suppl.5515","volume":"31","author":"Ray-Coquard","year":"2013","journal-title":"J. Clin. Oncol."},{"issue":"7","key":"10.1016\/j.ygyno.2021.09.025_bb0070","doi-asserted-by":"crossref","first-page":"2996","DOI":"10.1158\/0008-5472.CAN-08-3153","article-title":"Hyperactivation of the insulin-like growth factor receptor I signaling pathway is an essential event for cisplatin resistance of ovarian cancer cells","volume":"69","author":"Eckstein","year":"2009","journal-title":"Cancer Res."},{"issue":"6","key":"10.1016\/j.ygyno.2021.09.025_bb0075","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0100165","article-title":"Insulin-like growth factor 2 silencing restores taxol sensitivity in drug resistant ovarian cancer","volume":"9","author":"Brouwer-Visser","year":"2014","journal-title":"PLoS One"},{"issue":"5","key":"10.1016\/j.ygyno.2021.09.025_bb0080","doi-asserted-by":"crossref","first-page":"442","DOI":"10.1093\/jjco\/hyu034","volume":"44","author":"Okusaka","year":"2014","journal-title":"Jpn. J. Clin. Oncol."},{"issue":"34","key":"10.1016\/j.ygyno.2021.09.025_bb0085","doi-asserted-by":"crossref","first-page":"5800","DOI":"10.1200\/JCO.2009.23.6745","article-title":"Phase I, pharmacokinetic, and pharmacodynamic study of AMG 479, a fully human monoclonal antibody to insulin-like growth factor receptor 1","volume":"27","author":"Tolcher","year":"2009","journal-title":"J. Clin. Oncol."},{"issue":"10","key":"10.1016\/j.ygyno.2021.09.025_bb0090","doi-asserted-by":"crossref","DOI":"10.1093\/jnci\/dju249","article-title":"Prognostic and therapeutic relevance of molecular subtypes in high-grade serous ovarian cancer","volume":"106","author":"Konecny","year":"2014","journal-title":"J. Natl. Cancer Inst."},{"issue":"42","key":"10.1016\/j.ygyno.2021.09.025_bb0095","doi-asserted-by":"crossref","first-page":"39684","DOI":"10.1074\/jbc.M202766200","article-title":"Insulin\/insulin-like growth factor I hybrid receptors have different biological characteristics depending on the insulin receptor isoform involved","volume":"277","author":"Pandini","year":"2002","journal-title":"J. Biol. Chem."},{"issue":"45","key":"10.1016\/j.ygyno.2021.09.025_bb0100","doi-asserted-by":"crossref","first-page":"14326","DOI":"10.1021\/bi9613032","article-title":"Characterization of a hybrid receptor formed by dimerization of the insulin receptor-related receptor (IRR) with the insulin receptor (IR): coexpression of cDNAs encoding human IRR and human IR in NIH-3T3 cells","volume":"35","author":"Jui","year":"1996","journal-title":"Biochemistry."},{"issue":"24","key":"10.1016\/j.ygyno.2021.09.025_bb0105","doi-asserted-by":"crossref","first-page":"2730","DOI":"10.1038\/onc.2010.640","article-title":"Efficacy of and resistance to anti-IGF-1R therapies in Ewing\u2019s sarcoma is dependent on insulin receptor signaling","volume":"30","author":"Garofalo","year":"2011","journal-title":"Oncogene."},{"issue":"1","key":"10.1016\/j.ygyno.2021.09.025_bb0110","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1038\/sj.onc.1204050","article-title":"Activation of ErbB-2 via a hierarchical interaction between ErbB-2 and type I insulin-like growth factor receptor in mammary tumor cells","volume":"20","author":"Bala\u00f1\u00e1","year":"2001","journal-title":"Oncogene."},{"issue":"31","key":"10.1016\/j.ygyno.2021.09.025_bb0115","doi-asserted-by":"crossref","first-page":"27643","DOI":"10.1074\/jbc.M108863200","article-title":"Activation of BAD by therapeutic inhibition of epidermal growth factor receptor and transactivation by insulin-like growth factor receptor","volume":"277","author":"Gilmore","year":"2002","journal-title":"J. Biol. Chem."},{"issue":"9","key":"10.1016\/j.ygyno.2021.09.025_bb0120","doi-asserted-by":"crossref","first-page":"2589","DOI":"10.1158\/1535-7163.MCT-08-0493","article-title":"HER receptor signaling confers resistance to the insulin-like growth factor-I receptor inhibitor, BMS-536924","volume":"7","author":"Haluska","year":"2008","journal-title":"Mol. Cancer Ther."},{"issue":"20","key":"10.1016\/j.ygyno.2021.09.025_bb0125","doi-asserted-by":"crossref","first-page":"10100","DOI":"10.1158\/0008-5472.CAN-06-1684","article-title":"Heterodimerization of insulin-like growth factor receptor\/epidermal growth factor receptor and induction of survivin expression counteract the antitumor action of erlotinib","volume":"66","author":"Morgillo","year":"2006","journal-title":"Cancer Res."},{"issue":"3","key":"10.1016\/j.ygyno.2021.09.025_bb0130","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1016\/j.bbrc.2007.02.012","article-title":"The EGF receptor interacts with the type 1 IGF receptor and regulates its stability","volume":"355","author":"Riedemann","year":"2007","journal-title":"Biochem. Biophys. Res. Commun."},{"issue":"6","key":"10.1016\/j.ygyno.2021.09.025_bb0135","doi-asserted-by":"crossref","first-page":"748","DOI":"10.2174\/156800909789271495","article-title":"Crosstalk between epidermal growth factor receptor- and insulin-like growth factor-1 receptor signaling: implications for cancer therapy","volume":"9","author":"van der Veeken","year":"2009","journal-title":"Curr. Cancer Drug Targets"},{"issue":"15","key":"10.1016\/j.ygyno.2021.09.025_bb0140","doi-asserted-by":"crossref","first-page":"1849","DOI":"10.1200\/JCO.2011.37.2359","article-title":"Phase II study of ganitumab, a fully human anti-type-1 insulin-like growth factor receptor antibody, in patients with metastatic Ewing family tumors or desmoplastic small round cell tumors","volume":"30","author":"Tap","year":"2012","journal-title":"J. Clin. Oncol."},{"issue":"1","key":"10.1016\/j.ygyno.2021.09.025_bb0145","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1038\/ng872","article-title":"beta-cell-specific deletion of the Igf1 receptor leads to hyperinsulinemia and glucose intolerance but does not alter beta-cell mass","volume":"31","author":"Kulkarni","year":"2002","journal-title":"Nat. Genet."},{"issue":"3","key":"10.1016\/j.ygyno.2021.09.025_bb0150","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1007\/s00280-012-1924-9","article-title":"Phase 1 study of ganitumab (AMG 479), a fully human monoclonal antibody against the insulin-like growth factor receptor type I (IGF1R), in Japanese patients with advanced solid tumors","volume":"70","author":"Murakami","year":"2012","journal-title":"Cancer Chemother. Pharmacol."},{"issue":"7","key":"10.1016\/j.ygyno.2021.09.025_bb0155","doi-asserted-by":"crossref","first-page":"1777","DOI":"10.1093\/annonc\/mdt057","article-title":"A randomized, placebo-controlled phase 2 study of ganitumab or conatumumab in combination with FOLFIRI for second-line treatment of mutant KRAS metastatic colorectal cancer\u2020","volume":"24","author":"Cohn","year":"2013","journal-title":"Ann. Oncol."},{"issue":"12","key":"10.1016\/j.ygyno.2021.09.025_bb0160","doi-asserted-by":"crossref","first-page":"3414","DOI":"10.1158\/1078-0432.CCR-11-3369","article-title":"Safety and pharmacokinetics of ganitumab (AMG 479) combined with sorafenib, panitumumab, erlotinib, or gemcitabine in patients with advanced solid tumors","volume":"18","author":"Rosen","year":"2012","journal-title":"Clin. Cancer Res."},{"issue":"3","key":"10.1016\/j.ygyno.2021.09.025_bb0165","doi-asserted-by":"crossref","first-page":"532","DOI":"10.1016\/j.ygyno.2011.05.023","article-title":"Prognostic significance of the relative dose intensity of chemotherapy in primary treatment of epithelial ovarian cancer","volume":"122","author":"Fauci","year":"2011","journal-title":"Gynecol. Oncol."},{"issue":"5","key":"10.1016\/j.ygyno.2021.09.025_bb0170","doi-asserted-by":"crossref","first-page":"921","DOI":"10.1093\/annonc\/mdv027","article-title":"A phase 3 randomized, double-blind, placebo-controlled trial of ganitumab or placebo in combination with gemcitabine as first-line therapy for metastatic adenocarcinoma of the pancreas: the GAMMA trial","volume":"26","author":"Fuchs","year":"2015","journal-title":"Ann. Oncol."},{"issue":"11","key":"10.1016\/j.ygyno.2021.09.025_bb0175","doi-asserted-by":"crossref","first-page":"2834","DOI":"10.1093\/annonc\/mds142","article-title":"A randomized, placebo-controlled phase 2 study of ganitumab (AMG 479) or conatumumab (AMG 655) in combination with gemcitabine in patients with metastatic pancreatic cancer","volume":"23","author":"Kindler","year":"2012","journal-title":"Ann. Oncol."},{"issue":"3","key":"10.1016\/j.ygyno.2021.09.025_bb0180","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1016\/S1470-2045(13)70026-3","article-title":"Ganitumab with either exemestane or fulvestrant for postmenopausal women with advanced, hormone-receptor-positive breast cancer: a randomised, controlled, double-blind, phase 2 trial","volume":"14","author":"Robertson","year":"2013","journal-title":"Lancet Oncol."},{"issue":"16","key":"10.1016\/j.ygyno.2021.09.025_bb0185","doi-asserted-by":"crossref","first-page":"4240","DOI":"10.1158\/1078-0432.CCR-13-2752","article-title":"Randomized phase Ib\/II trial of rilotumumab or ganitumab with panitumumab versus panitumumab alone in patients with wild-type KRAS metastatic colorectal cancer","volume":"20","author":"Van Cutsem","year":"2014","journal-title":"Clin. Cancer Res."},{"issue":"7","key":"10.1016\/j.ygyno.2021.09.025_bb0190","doi-asserted-by":"crossref","first-page":"1925","DOI":"10.1158\/1078-0432.CCR-13-1869","article-title":"Phase II randomized study of figitumumab plus docetaxel and docetaxel alone with crossover for metastatic castration-resistant prostate cancer","volume":"20","author":"de Bono","year":"2014","journal-title":"Clin. Cancer Res."},{"issue":"19","key":"10.1016\/j.ygyno.2021.09.025_bb0195","doi-asserted-by":"crossref","first-page":"2059","DOI":"10.1200\/JCO.2013.54.4932","article-title":"Randomized, phase III trial of first-line figitumumab in combination with paclitaxel and carboplatin versus paclitaxel and carboplatin alone in patients with advanced non-small-cell lung cancer","volume":"32","author":"Langer","year":"2014","journal-title":"J. Clin. Oncol."},{"issue":"3","key":"10.1016\/j.ygyno.2021.09.025_bb0200","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1093\/annonc\/mdu517","article-title":"Randomized, phase III trial of figitumumab in combination with erlotinib versus erlotinib alone in patients with nonadenocarcinoma nonsmall-cell lung cancer","volume":"26","author":"Scagliotti","year":"2015","journal-title":"Ann. Oncol."},{"issue":"1","key":"10.1016\/j.ygyno.2021.09.025_bb0205","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1186\/2162-3619-3-26","article-title":"Activity of dalotuzumab, a selective anti-IGF1R antibody, in combination with erlotinib in unselected patients with non-small-cell lung cancer: a phase I\/II randomized trial","volume":"3","author":"Moran","year":"2014","journal-title":"Exp. Hematol. Oncol."},{"issue":"12","key":"10.1016\/j.ygyno.2021.09.025_bb0210","doi-asserted-by":"crossref","first-page":"djv258","DOI":"10.1093\/jnci\/djv258","article-title":"A randomized phase II\/III study of dalotuzumab in combination with cetuximab and irinotecan in chemorefractory, KRAS wild-type, metastatic colorectal cancer","volume":"107","author":"Sclafani","year":"2015","journal-title":"J. Natl. Cancer Inst."},{"issue":"13","key":"10.1016\/j.ygyno.2021.09.025_bb0215","doi-asserted-by":"crossref","first-page":"2253","DOI":"10.1002\/cncr.29308","volume":"121","author":"Hanna","year":"2015","journal-title":"Cancer."},{"issue":"19","key":"10.1016\/j.ygyno.2021.09.025_bb0220","doi-asserted-by":"crossref","first-page":"2980","DOI":"10.1002\/cncr.28744","volume":"120","author":"Philip","year":"2014","journal-title":"Cancer."},{"issue":"3","key":"10.1016\/j.ygyno.2021.09.025_bb0225","doi-asserted-by":"crossref","first-page":"1337","DOI":"10.1210\/endo.132.3.7679979","article-title":"Characterization of the affinities of insulin-like growth factor (IGF)-binding proteins 1-4 for IGF-I, IGF-II, IGF-I\/insulin hybrid, and IGF-I analogs","volume":"132","author":"Oh","year":"1993","journal-title":"Endocrinology."},{"issue":"7","key":"10.1016\/j.ygyno.2021.09.025_bb0230","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1038\/nrc1387","article-title":"Insulin-like growth factors and neoplasia","volume":"4","author":"Pollak","year":"2004","journal-title":"Nat. Rev. Cancer"},{"issue":"11","key":"10.1016\/j.ygyno.2021.09.025_bb0235","doi-asserted-by":"crossref","first-page":"2243","DOI":"10.1038\/s41388-020-1154-2","article-title":"IGFBP2: integrative hub of developmental and oncogenic signaling network","volume":"39","author":"Li","year":"2020","journal-title":"Oncogene."},{"key":"10.1016\/j.ygyno.2021.09.025_bb0240","doi-asserted-by":"crossref","first-page":"108307","DOI":"10.1016\/j.mrrev.2020.108307","article-title":"Nuclear localization and actions of the insulin-like growth factor 1 (IGF-1) system components: transcriptional regulation and DNA damage response","volume":"784","author":"Poreba","year":"2020","journal-title":"Mutat. Res."}],"container-title":["Gynecologic Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S009082582101413X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S009082582101413X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,25]],"date-time":"2025-09-25T03:57:56Z","timestamp":1758772676000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S009082582101413X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,12]]},"references-count":48,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2021,12]]}},"alternative-id":["S009082582101413X"],"URL":"https:\/\/doi.org\/10.1016\/j.ygyno.2021.09.025","relation":{},"ISSN":["0090-8258"],"issn-type":[{"value":"0090-8258","type":"print"}],"subject":[],"published":{"date-parts":[[2021,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Results of TRIO-14, a phase II, multicenter, randomized, placebo-controlled trial of carboplatin-paclitaxel versus carboplatin-paclitaxel-ganitumab in newly diagnosed epithelial ovarian cancer","name":"articletitle","label":"Article Title"},{"value":"Gynecologic Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ygyno.2021.09.025","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 The Authors. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}